Anthera Pharmaceuticals, a biotech developing a Phase 3 anti-inflammatory treatment for acute coronary syndrome, raised $42 million by offering 6 million shares at $7 per share after originally filing to raise almost $65 million by offering 4.6 million shares at a range of $13-$15. Venture backers indicated an interest in purchasing almost 37% of the deal, or 2.2 million shares. Deutsche Bank acted as the lead underwriter on the deal, which began trading today on the NASDAQ.
